• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

A Slow Death to PAR & Endo





















Where are all the PAR North folks now? Sales Team??? I thought it was easier to sell moonshine than our Qualitest products..... Looks like you fucktards can't even sell your products.
 












All you folks that thought you knew more are finding out how shady the leaders that took over after Rajiv. Pure Worthless.
The moment Endo bought PAR was the start of the downfall of death. PAR leadership destroyed the company. PAR was purchased due to their pipe of First to File ANDA's, but what was purchased was a bunch of worthless paper. None of those First to File were worth anything.